AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | MicrobiomeTrials← Back to trialsNCT07649304
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-10-09Est. Completion: 2028-04-30
Enrollment target: 15 participants Other microbiome trials you might be interested in
AIDS-Related Burkitt LymphomaAIDS-Related Diffuse Large B-cell LymphomaAIDS-Related Plasmablastic LymphomaAIDS-Related Primary Effusion LymphomaHIV InfectionAIDS Related Non-Hodgkin Lymphoma
This pilot clinical trial studies gene therapy following combination chemotherapy in treating patients with acquired imm…
Bethesda, United StatesEst. completion Aug 9, 2027
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, predniso…
La Jolla, United StatesEst. completion Oct 10, 2024